



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock Code 股份代號: 503)

10 September 2014

Dear Sir/Madam,

Letter to New Shareholders Election of Language and Means of Receipt of Corporate Communication(s)

Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association of Lansen Pharmaceutical Holdings Limited (the “Company”), the Company will make available the following options for you to elect for the receipt of future corporate communication(s) (“Corporate Communication(s)”) of the Company, which means any document(s) issued or to be issued by the Company for the information or action of any holders of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditor’s report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form, in the following manners:

- (1) to read future Corporate Communication(s) published on the Company’s website at www.lansen.com.cn (“Website Version”) in place of receiving printed copies, and receive a notification letter of the publication of the Corporate Communication(s) on the website; or
- (2) to receive both the printed English and Chinese versions of all future Corporate Communication(s).

In support of environmental protection and for the purpose of cost saving, the Company recommends you to select the Website Version. To make your election, please complete the reply form (“Reply Form”) on the reverse side and sign and return it to the Company’s Hong Kong share registrar (the “Hong Kong Share Registrar”), Tricor Investor Services Limited, by post using the pre-paid mailing label provided (if you post in Hong Kong) or hand delivered. Otherwise, please affix appropriate postage.

If you do not complete the Reply Form and return it to the Hong Kong Share Registrar at the address indicated above by 10 October 2014, you will be deemed to consent to receiving the Website Version only, and a printed notification letter of the publication of the Corporate Communication(s) on the website will be sent to you. If an email address is provided by you in the Reply Form, an electronic version of the notification letter of the publication of the Corporate Communication(s) on the website will be sent to you.

You have the right at any time by reasonable notice in writing to the Company (c/o Tricor Investor Services Limited) or by email to lansen-ecom@hk.tricorglobal.com to change the choice of language and means of receipt of the Corporate Communication(s). Even if you have chosen to receive all future Corporate Communication(s) using electronic means but for any reason have difficulty in receiving or gaining access to the Corporate Communication(s), the Company will, upon your request, promptly send the Corporate Communication(s) to you in printed form free of charge.

Please note that (a) printed copies of the English and Chinese versions of all future Corporate Communication(s) will be available from the Company or the Hong Kong Share Registrar upon request; and (b) the same will also be available on the Company’s website at www.lansen.com.cn and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

Should you have any queries in relation to this letter, please call the hotline of the Company’s Hong Kong Share Registrar at +852 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Lansen Pharmaceutical Holdings Limited
Stephen Burnau Hunt
Chairman

敬啟者：

致新登記股東之函件 選擇收取公司通訊文件之語言版本及收取方式

根據香港聯合交易所有限公司證券上市規則及朗生醫藥控股有限公司（「本公司」）之組織章程細則，本公司將向閣下提供下列方案，選擇以下列方式收取本公司日後之公司通訊文件（「公司通訊文件」），即本公司發出或將發出以供其任何證券持有人參照或採取行動之任何文件，包括但不限於(a)董事會報告、其年度賬目連同核數師報告及其財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；及(f)代表委任表格：

- (1) 瀏覽於本公司網站www.lansen.com.cn所刊載日後公司通訊文件（「網上版本」），以代替收取印刷本，及收取有關刊載公司通訊文件之通知；或
- (2) 同時收取所有日後公司通訊文件英文及中文版印刷本。

為積極響應環保並節省成本，本公司建議閣下選擇收取網上版本。請閣下填妥本函背面之回條（「回條」），並在回條上簽署，利用預付郵寄標籤寄回（如在香港投寄）或親身交回本公司之香港股份過戶登記處卓佳證券登記有限公司。否則請貼上適當之郵資。

倘閣下在二零一四年十月十日仍未填妥回條及按上述地址將其交回香港股份過戶登記處，則閣下將被視為已同意僅收取通訊文件之網上版本，而本公司將向閣下寄發有關刊載公司通訊文件之通知函件。倘閣下在回條填上電郵地址，則本公司將向閣下發送有關刊載公司通訊文件之電子通知。

閣下有權隨時通過卓佳證券登記有限公司或發送電郵至lansen-ecom@hk.tricorglobal.com向本公司發出合理書面通知，以更改收取公司通訊文件語言版本及收取方式之選擇。即使閣下選擇以電子途徑收取日後所有公司通訊文件，惟如因任何理由導致收取或接收公司通訊文件時遇上困難，則本公司將於接獲閣下要求後，隨即向閣下免費寄發公司通訊文件之印刷本。

請注意(a) 閣下可向本公司或香港股份過戶登記處要求索取所有日後公司通訊文件之英文及中文印刷本；及(b)有關文件亦會在本公司網站www.lansen.com.cn及香港交易所披露易網站www.hkexnews.hk刊載。

倘閣下對此函件有任何疑問，請於星期一至星期五（公眾假期除外）辦公時間上午九時至下午六時，致電本公司香港股份過戶登記處電話熱線+852 2980 1333查詢。

朗生醫藥控股有限公司
主席
Stephen Burnau Hunt
謹啟

二零一四年九月十日

Reply Form 回條

To: Lansen Pharmaceutical Holdings Limited (the “Company”)
(Stock Code: 503)
c/o Tricor Investor Services Limited
Level 22, Hopewell Centre
183 Queen’s Road East, Hong Kong

致: 朗生醫藥控股有限公司（「公司」）
(股份代號: 503)
經卓佳證券登記有限公司
香港皇后大道東 183 號
合和中心 22 樓

I/We would like to receive the corporate communication(s) of the Company (“Corporate Communication(s)”) as indicated below:

本人／我們希望以下列方式收取 貴公司之公司通訊（「公司通訊文件」）；

(Please mark **ONLY ONE (X)** of the following boxes)

（請從下列選擇中，僅在**其中一個**空格內劃上（X）號）

☐ read the **Website Version** of all future Corporate Communication(s) published on the Company’s website in place of receiving printed copies, and to receive an **email notification** of the posting of the Corporate Communication(s) on the Company’s website to my/our **email address** _____; **OR**

瀏覽在公司網站發佈之公司通訊**網上版本**，以代替印刷本，並收取有關公司通訊登載在公司網站的**電郵通知**，電郵通知請發送至本人／吾等之**電郵地址** _____；或

☐ to receive **both the printed English and Chinese versions** of all future Corporate Communication(s).
同時收取公司通訊文件之**英文及中文印刷本**。

Signature
簽名

Phone Number
聯絡電話

Name
姓名

(English)

(Chinese)

Notes:
附註:

- Please provide your email address if you wish to receive the notification letter via email. If no email address is provided, a printed copy of the notification letter will be sent to you by post when Corporate Communication(s) is/are posted on the Company’s website.
如果 閣下希望通過電郵收取通知信函，請提供 閣下的電郵地址。如果 閣下沒有提供電郵地址，本公司將向 閣下寄發有關已在本公司網站刊載的公司通訊文件之通知信函印刷本。
- Corporate Communication(s) refer to any document(s) issued or to be issued by the Company for the information or action of any holders of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditor’s report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
公司通訊文件指本公司發出或將發出以供其任何證券持有人參照或採取行動之任何文件，包括但不限於(a) 董事會報告、其年度賬目連同核數師報告及其財務摘要報告（如適用）；(b) 中期報告及中期摘要報告（如適用）；(c) 會議通告；(d) 上市文件；(e) 通函；及(f) 代表委任表格。
- If the Company does not receive this Reply Form by 10 October 2014, all future Corporate Communication(s) will be sent out in the manner specified in the Letter to New Shareholders dated 10 September 2014.
倘若本公司於 2014 年 10 月 10 日仍未收到 閣下的回條，本公司將按 2014 年 9 月 10 日之致新登記股東之函件內所述之方式把公司通訊寄予 閣下。
- By selection to read the Website Version of the Corporate Communication(s) published on the Company’s website in place of receiving printed copies, you have expressly consented to waive the right to receive the Corporate Communication(s) in printed form.
在選擇瀏覽網上版本以代替收取印刷本後，閣下已明示同意放棄收取公司通訊印刷本的權利。
- If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Reply Form in order to be valid.
如屬聯名股東，則本回條須由該名於本公司名冊上就聯名持有股份其姓名位列首位的股東簽署，方為有效。
- The above instructions will apply to all future Corporate Communication(s) to be sent to shareholders of the Company until you notify otherwise by reasonable notice in writing to the Company c/o the Hong Kong Share Registrar of the Company, Tricor Investor Services Limited, at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong or by email to lansen-ecom@hk.tricorglobal.com.
上述指示適用於將寄發予本公司股東之所有公司通訊，直至 閣下發出合理時間的書面通知予本公司之香港股份過戶登記處卓佳證券登記有限公司，地址為香港皇后大道東 183 號合和中心 22 樓或以電郵方式發送至 lansen-ecom@hk.tricorglobal.com 另作選擇為止。
- Shareholders are entitled to change the choice of means of receipt or language of the Corporate Communication(s) at any time by reasonable notice in writing to the Company c/o Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong or by email to lansen-ecom@hk.tricorglobal.com.
股東有權隨時發出合理時間的書面通知本公司經卓佳證券登記有限公司，地址為香港皇后大道東 183 號合和中心 22 樓或以電郵方式發送至 lansen-ecom@hk.tricorglobal.com，要求更改收取公司通訊之語言版本及方式。
- This Reply Form with no box marked, with more than one box marked, or otherwise incorrectly completed will be voided at the discretion of the Company.
在本回條上，如沒有在方格內劃上 (X) 號，或在超過一個方格內劃上 (X) 號或填寫不正確，在本公司酌情決定後將告無效。

(Please cut along the dotted line 請沿虛線剪下)



Please cut and paste the mailing label onto an envelope and return the Request Form to us.

No postage is required for local mailing

當 閣下寄回此表格時，請將此郵寄標籤剪貼於信封上。

如在本港投寄，閣下無需支付郵費或貼上郵票

Mailing Label 郵寄標籤

Tricor Investor Services Limited
卓佳證券登記有限公司
Freepost No. 簡便回郵號碼 : 37
Hong Kong 香港